Global Antimicrobial Resistance Surveillance System (GLASS) - The detection and reporting of colistin resistance by Bortolaia, Valeria et al.
 
 
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright 
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
 Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
 You may not further distribute the material or use it for any profit-making activity or commercial gain 
 You may freely distribute the URL identifying the publication in the public portal 
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
  
 
   
 
 
Downloaded from orbit.dtu.dk on: Mar 30, 2019
Global Antimicrobial Resistance Surveillance System (GLASS) - The detection and
reporting of colistin resistance
Bortolaia, Valeria; Dekhnich, Andrey ; Hendriksen, Rene S.; Kozlov, Roman; Patel, Jean;
Paveenkittiporn, Wantana ; Perovic, Olga; Rebelo, Ana Rita; Woodford, Neil
Publication date:
2018
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Bortolaia, V., Dekhnich, A., Hendriksen, R. S., Kozlov, R., Patel, J., Paveenkittiporn, W., ... Woodford, N. (2018).
Global Antimicrobial Resistance Surveillance System (GLASS) - The detection and reporting of colistin
resistance. World Health Organization.
                                                                                   
 
Global Antimicrobial Resistance  
Surveillance System  
(GLASS) 
 
The detection and reporting of 
colistin resistance 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
Global Antimicrobial Resistance  
Surveillance System  
(GLASS) 
 
The detection and reporting of 
colistin resistance 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© World Health Organization 2018 
 
 
All rights reserved. Publications of the World Health Organization are available on the WHO website 
(http://www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue 
Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: 
bookorders@who.int).  
 
Requests for permission to reproduce or translate WHO publications – whether for sale or for non-
commercial distribution – should be addressed to WHO Press through the WHO website 
(http://www.who.int/about/licensing/copyright_form/en/index.html).  
 
The designations employed and the presentation of the material in this publication do not imply the 
expression of any opinion whatsoever on the part of the World Health Organization concerning the 
legal status of any country, territory, city or area or of its authorities, or concerning the delimitation 
of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines 
for which there may not yet be full agreement.  
 
The mention of specific companies or of certain manufacturers’ products does not imply that they 
are endorsed or recommended by the World Health Organization in preference to others of a similar 
nature that are not mentioned. Errors and omissions excepted, the names of proprietary products 
are distinguished by initial capital letters.  
 
All reasonable precautions have been taken by the World Health Organization to verify the 
information contained in this publication. However, the published material is being distributed 
without warranty of any kind, either expressed or implied. The responsibility for the interpretation 
and use of the material lies with the reader. In no event shall the World Health Organization be 
liable for damages arising from its use.  
 
 
5 
 
Acknowledgements 
WHO thanks the following authors and contributors at WHO collaborating centres: Valeria 
Bortolaia, Andrey Dekhnich, Rene S. Hendriksen, Roman Kozlov, Jean Patel, Wantana 
Paveenkittiporn, Olga Perovic, Ana Rita Rebelo and Neil Woodford. 
Contributions by staff at the WHO regional offices: Sheick Oumar Coulibaly, Walter Fuller, Laetitia 
Gahimbare for the Regional Office for Africa (AFRO); Marcelo Galas and Ramon Pardo Pilar at the 
Regional Office for the Americas (PAHO); Mona Elshokry and Franciscus Konings at the Regional 
Office for the Eastern Mediterranean (EMRO); Danilo Lo Fo Wong at the Regional Office for Europe 
(EURO); Aparna Singh Shah and Sirenda Vong at the Regional Office for South East Asia (SEARO); 
and Socorro Escalante, Raynal Squires and Babatunde Olowokure at the Regional Office for the 
Western Pacific (WPRO). 
External reviewers:  Anette M. Hammerum (Statens Serum Institute, Copenhagen, Denmark); 
Rumina Hasan (Aga Khan University, Karachi, Pakistan); Maria Karlsson and Joseph Lutgring 
(Centers for Disease Control and Prevention, Atlanta (GA), USA); Erika Matuschek (European 
Committee on Antimicrobial Susceptibility Testing) and Gregory Tyson (Food and Drug 
Administration, Silver Spring (MD), USA).  
WHO staff: Jorge Raul Matheu Alvarez, Sebastien Cognat, Sergey Romualdovich Eremin, Marcelo 
Galas, Sapna Manglani, Christopher Oxenford and Carmem Lucia Pessoa-Silva. 
 
Developer group:  
Rene S. Hendriksen, Jean Patel, Sapna Manglani, Neil Woodford 
 
Executive group:  
Rene S. Hendriksen, Carmem Lucia Pessoa-Silva 
 
Editing 
Elisabeth Heseltine  
 
Financial support:  
The Government of the United States of America 
 
 
 
Version 1 
Publication date: December 2018 
6 
 
Acronyms and abbreviations 
AMR  antimicrobial resistance 
CLSI   Clinical and Laboratory Standards Institute 
EUCAST European Committee on Antimicrobial Susceptibility Testing 
GLASS  Global Antimicrobial Resistance Surveillance System  
PCR   polymerase chain reaction  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
Table of contents  
 
Summary………………………………………………………………………………………….. 8 
1. Introduction ………………………………………………………………………………… 8 
2. Acquired resistance to colistin……………………………………………………... 9 
 2.1 Mutational colistin resistance………………………………………………….9 
 2.2 Transferrable colistin resistance………………………………………………9 
3. Laboratory detection of colistin resistance………………………………….. 10 
 3.1 Phenotypic methods……………………………………………………………… 10 
 3.2. Genotypic methods…………………………………………………………………12 
4. Surveillance strategies………………………………………………………………….13 
5. References……………………………………………………………………………………14 
 
 
 
 
  
8 
 
Summary 
The scope of this technical note is to review current methods for the detection of colistin 
resistance and to provide a framework for its investigation. The document highlights the 
critical distinction between phenotypic detection of colistin resistance and genotypic 
detection of specific colistin resistance mechanisms, such as mcr and chromosomal 
mutations. Colistin resistance in Enterobacteriaceae and Acinetobacter baumannii is 
included in the WHO Global Antimicrobial Resistance Surveillance System (GLASS). 
Currently, however, reliable tests for phenotypic detection of colistin resistance for clinical 
and surveillance purposes are not widely available. 
The technical note describes existing phenotypic methods for detecting colistin resistance, 
genotypic methods for detecting specific colistin resistance mechanisms and surveillance 
strategies for monitoring colistin resistance.  
This is a rapidly evolving field with new resistance genes being identified regularly and new 
methods for phenotypic resistance testing being described, hence this document will be 
updated, as needed, to reflect these developments.  
 
1. Introduction 
Colistin belongs to a group of antimicrobial agents known as polymyxins, which were 
originally isolated from the spore-forming soil organism Paenibacillus polymyxa. Molecules in 
this group are polymyxins A, B, C, D and E, of which only polymyxin E (colistin) and 
polymyxin B are used clinically in humans.  
Colistin is a mixture of polymyxin E1 and E2, two bactericidal pentacationic lipopeptides. 
The mode of action of colistin is not fully elucidated but involves binding to 
lipopolysaccharides and phospholipids in the outer membrane of Gram-negative organisms, 
which results in membrane disruption and cell death. Colistin is active against a wide variety 
of Gram-negative bacteria and is not active against Gram-positive bacteria, which lack an 
outer membrane.  
Colistin is used in both human and veterinary medicine. In humans, colistin is generally used 
to treat infections with multidrug-resistant, extensively drug-resistant and pan drug-resistant 
bacteria (1). It is usually administered by injection or inhalation (the latter, for example, for 
patients with cystic fibrosis) as the sodium salt of colistin methanesulfonate, which is an 
inactive prodrug. It is considered less toxic than colistin sulfate, which is used orally (with 
very limited absorption) or topically (2).  
In veterinary medicine, colistin has been widely used in various food-producing animals 
(broiling and laying hens, pigs, calves, beef cattle, dairy cattle, meat- and milk-producing 
sheep and goats, rabbits and fish in aquaculture) for the prevention and treatment of 
infections caused by Enterobacteriaceae and other Gram-negative bacteria and for growth 
promotion. In veterinary medicine, colisitin is usually administered orally (3). The wide use of 
colistin in food-producing animals is considered to have contributed extensively to the 
emergence of resistance to this drug (3–5).  
With the spread of highly resistant bacteria such as carbapenemase-producing 
Enterobacteriaceae and multi-drug resistant Pseudomonas aeruginosa and Acinetobacter 
baumannii, colistin has been used increasingly as an agent of last resort. The emergence of 
colistin resistance in multidrug-resistant bacteria is therefore a significant clinical and public 
health concern (6–8). 
The spectrum of colistin (Table 1) includes activity in vitro against Acinetobacter spp., 
Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., Escherichia coli, Salmonella 
spp., Shigella spp., Citrobacter spp., Yersinia pseudotuberculosis and Haemophilus 
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influenzae. Furthermore, colistin has considerable activity against Stenotrophomonas spp., 
whereas it is not active against some Gram-negative aerobic bacilli, including Burkholderia 
mallei, Burkholderia cepacia, Proteus spp., Providencia spp., Morganella morganii, Serratia 
spp., Edwardsiella spp. and Brucella spp. (9–12), Gram-negative and Gram-positive aerobic 
cocci, Gram-positive aerobic bacilli, anaerobes, fungi and parasites (2, 13).  
 
Table 1. Activity of colistin against selected pathogenic bacteria 
Organism  Natural state (resistant or susceptible to polymyxins) 
Escherichia coli Susceptible  
Klebsiella spp. Susceptible  
Enterobacter spp. Susceptible  
Pseudomonas aeruginosa Susceptible  
Acinetobacter spp. Susceptible  
Salmonella spp. Susceptible  
Shigella spp. Susceptible  
Pasteurella spp. Susceptible  
Haemophilus spp. Susceptible  
Proteus spp. Intrinsically resistant  
Providencia spp. Intrinsically resistant  
Morganella morganii Intrinsically resistant  
Serratia spp. Intrinsically resistant  
Brucella spp. Intrinsically resistant  
Neisseria spp. Intrinsically resistant  
Chromobacterium spp. Intrinsically resistant  
Burkholderia spp. Intrinsically resistant  
Gram-positive bacteria  
 
All Gram-positive bacteria are intrinsically resistant to polymyxins 
because of the absence of an outer membrane.  
 
 
2.  Acquired resistance to colistin 
2.1  Mutational colistin resistance 
Acquired resistance to polymyxins in naturally susceptible species is usually the result of 
modifications of the bacterial cell surface, including alterations to the lipopolysaccharide 
structure. Other reported resistance mechanisms include shedding of capsular 
polysaccharides, which trap or bind polymyxins, as found in some isolates of Klebsiella 
pneumoniae (14). In A. baumannii, two primary mechanisms of chromosomally mediated 
colistin resistance have been described. The first is due to loss of lipopolysaccharide 
production and the second to modification of the system that allows bacteria to respond to 
environmental conditions, affecting lipid modification and reducing bacterial membrane 
permeability (14, 15). Resistance arising from chromosomal mutations is not usually 
transferred horizontally among bacteria (16).  
 
2.2  Transferrable colistin resistance 
A plasmid-mediated gene that confers resistance to colistin, mcr-1, was first reported in late 
2015 in E. coli isolates from food animals and their meat collected in China during 2011–
2014 and in E. coli and K. pneumoniae isolates collected from human patients in China in 
2014 (17). Although colistin had been used extensively in food-producing animals globally 
for many years, it was not available for human clinical use in China until 2017, suggesting 
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that the selection pressure for the spread of mcr-1 was driven by veterinary use of colistin 
(18).  
Shortly after this first description, it was observed that the mcr-1 gene had spread globally in 
K. pneumoniae, E. coli, Enterobacter cloacae and Salmonella spp. isolates of animal, 
environmental and human origin (17, 19–25). The global spread of mcr-1 was probably also 
facilitated by human travel, as suggested by the finding of the gene in enteric bacteria from 
travellers returning to Europe after visiting countries with a high prevalence of mcr-1 in South 
America, Asia and Africa (18, 26).  
After identification of mcr-1, wide scientific attention led to recognition of multiple mcr-1 
variants (27–35) and seven additional (at the time of writing) mcr gene families (36). The 
latter include mcr-2 in E. coli and Salmonella spp. from pigs, cattle and chickens in Belgium 
(37, 38), mcr-3 in human and animal E. coli, Proteus spp. and Aeromonas spp. in countries 
in Asia, Europe and South America (39), mcr-4 in E. coli and Salmonella enterica serovar 
Typhimurium from pigs and humans in Belgium, Italy and Spain (40, 41), mcr-5 in poultry 
and poultry meat isolates of S. enterica serovar Paratyphi B d-tartrate fermenting and in 
porcine E. coli in Germany (42, 43), mcr-6 in Moraxella sp. isolates from pigs in the United 
Kingdom (35), mcr-7 in K. pneumoniae from chickens in China (44, 45) and mcr-8 in K. 
pneumoniae from humans and pigs in China (46). The co-occurrence of more than one of 
these genes has been reported in E. coli and Salmonella spp. isolates of human and animal 
origin in Europe and China, such as the simultaneous presence of mcr-1 and mcr-3 and of 
mcr-1 and mcr-4 (47–51).  
Bacteria isolated from food-producing animals to date appear to carry the mcr genes more 
frequently than bacteria isolated from humans, which is probably a consequence of the 
selective pressure exerted by the wide use of colistin in veterinary practice (14). Importantly, 
mcr-mediated colistin resistance can be transferred among bacterial strains, species and 
genera. To limit further dissemination of such genes, accurate identification of colistin-
resistant, mcr-encoding isolates is of critical importance.  
 
3.  Laboratory detection of colistin resistance  
3.1  Phenotypic methods 
Testing for antimicrobial susceptibility by phenotypic methods is currently the cornerstone of 
AMR surveillance and is necessary to determine the occurrence of colistin resistance within 
GLASS. Phenotypic testing for antimicrobial susceptibility to colistin is, however, complex. 
The technical difficulties in phenotypic testing for colistin susceptibility include poor diffusion 
of polymyxins through agar, which compromises the performance of both disc diffusion and 
gradient diffusion methods, and the tendency of polymyxins to bind to the surface of plastics 
(e.g. the plastic of microtitre trays used for broth microdilution and of pipette tips) (52).  
International standard-setting organizations such as the Clinical and Laboratory Standards 
Institute (CLSI)1 and the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST)2 formed a joint polymyxin breakpoints working group in March 2016, which 
recommended only broth microdilution for testing of colistin susceptibility. Thus, the 
susceptibility of Enterobacteriaceae, P. aeruginosa and Acinetobacter spp. to colistin should 
be tested according to the International Organization for Standardization standard broth 
microdilution method (ISO 20776-1), in which cation-adjusted Mueller-Hinton broth is used. 
No additives may be included in any part of testing (in particular no polysorbate-80 or other 
                                                     
1 https://clsi.org/ 
2 http://www.eucast.org/ 
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surfactants), because, for example, polysorbate 80 can act synergistically with polymyxins 
and artificially lower the minimum inhibitory concentration (53). Trays should be made of 
plain polystyrene, and sulfate salts of polymyxins must be used (the methane sulfonate 
derivative of colistin cannot be used as it is an inactive pro-drug that breaks down slowly in 
solution). A review of the performance of different broth microdilution-based systems used 
for colistin susceptibility testing is available (54).  
Quality control is essential in phenotypic detection of colistin resistance. To ensure that the 
method used provides reliable results, inclusion of a strain with low-level colistin resistance 
(such as mcr-1-positive E. coli NCTC 13846) is recommended by EUCAST (55).  
Phenotypic results can be interpreted and reported as either the epidemiological cut-off 
(according to EUCAST or CLSI), which define wild-type and non-wild-type populations, or as 
clinical breakpoints, which define clinical susceptibility and resistance (Table 2) (56, 57).  
 
Table 2. Epidemiological cut-off values and clinical breakpoints  
Bacteria Wild type 
or 
sensitive 
Non-wild type or 
resistant 
Comment 
Enterobacteriaceae ≤ 2 µg/mL ≥ 4 µg/mL For CLSI, this is an epidemiological 
cut-off to distinguish between wild 
and non-wild types. 
Acinetobacter spp. ≤ 2 µg/mL ≥ 4 µg/mL Clinical breakpoints 
Pseudomonas aeruginosa ≤ 2 µg/mL ≥ 4 µg/mL Clinical breakpoints 
 
Clinical trials, including ones in which new antibiotics are compared, are providing new data 
on the clinical effectiveness of colistin for the treatment of infections caused by Gram-
negative bacteria. According to the clinical outcomes, colistin appears to be a poor mono-
therapeutic option, especially when other drugs are available (58). In particular, the dosing of 
colistin is complex, as its pharmacokinetics differs widely among patients (59). Therefore, 
further review of clinical outcomes is necessary to determine whether currently established 
breakpoints and epidemiological cut-off values accurately inform clinical decisions. See 
CLSI1 and EUCAST2 documents for the latest information.  
Testing for antimicrobial susceptibility by broth microdilution requires greater laboratory 
capacity than standard disc diffusion and gradient diffusion methods and other phenotypic 
methods. Nevertheless, other methods are either insufficiently accurate or have not yet 
undergone rigorous multicentre evaluation with large collections of bacteria, including 
different species (i.e. most Enterobacteriaceae and Gram-negative non-fermenters), that 
express all known colistin resistance mechanisms. Thus, these methods cannot yet be 
recommended as best practice. 
The methods that appear promising but are still to undergo the rigorous evaluation described 
above are: (i) agar-based screening media for bacteria suspected to be colistin-resistant (60, 
61), which should always be followed by further investigation of the colonies growing on 
such media by broth microdilution and/or molecular methods; (ii) the Rapid Polymyxin NP 
test (62); (iii) Colispot (54); and (iv) disc prediffusion (63). The performance of these 
methods depends on the bacterial species and the colistin resistance mechanisms. 
The recognized need for simpler, more reliable in vitro testing of colistin susceptibility and for 
methods to selectively identify colistin-resistant, mcr-positive isolates is driving technical 
development, and improved phenotypic testing products are expected to become available.  
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3.2 Genotypic methods 
During its early implementation stage (64), GLASS only collects data on antimicrobial 
susceptibility of target pathogens acquired by phenotypic testing; it does not yet collect data 
on the distribution of specific resistance mechanisms. Nevertheless, genotypic surveillance 
can be used as a basis for selection of isolates for subsequent phenotypic testing for 
antimicrobial susceptibility and the results submitted to GLASS, or it can be used as a 
supplementary investigation of resistance mechanisms for isolates with unusual phenotypic 
resistance(s). Such studies can help in understanding the epidemiology of AMR and the 
relative contributions of the human clinical, animal health and agricultural sectors to the 
problem of AMR. They may also improve reporting to the Emerging Antimicrobial Resistance 
module in GLASS (the GLASS-EAR system).  
Genotypic results should be reported as the presence or absence of the specified colistin 
resistance mechanism or gene. At present, there is insufficient understanding of acquired 
colistin resistance mechanisms to design a molecular test that would be sufficiently sensitive 
or specific to be recommended as best practice. In particular, genotypic methods would 
probably not detect all the diverse chromosomal mutations known to be responsible for most 
phenotypic colistin resistance in clinical settings (14) but would be limited to the detection of 
acquired colistin resistance genes. A few published and/or commercially available colistin 
molecular tests are available for detecting transferrable colistin resistance, including a 
multiplex polymerase chain reaction (PCR) for screening for mcr-1 to mcr-5. 
It should be noted that a negative result in a PCR molecular test cannot be used to predict 
susceptibility to colistin, because the test cannot exclude the presence of chromosomal 
mechanisms of resistance or even of novel mcr genes that are not included in the test. As 
evidence of this limitation, high rates of colistin resistance are reported among strains of K. 
pneumoniae producing carbapenemase in Brazil and Italy but which lack mcr genes (65). In 
these settings, a negative PCR result for mcr genes would have poor predictive value for a 
colistin-susceptible phenotype. Whole-genome sequencing would allow screening for mcr 
genes and known chromosomal mutations that confer colistin resistance (40). Bioinformatics 
analysis could be conducted with, among others, the Center for Genomic Epidemiology Web 
tools (66), and ResFinder 3.1.0 (database updated on 10 September 2018 to include all 
known mcr-genes and chromosomal point mutations) (67). Although the sensitivity and 
negative predictive value would be affected by inclusion of strains with novel mechanisms of 
resistance, this is the most comprehensive method for detecting all currently known putative 
colistin resistance mechanisms. It will also enable retrospective analysis of sequencing data 
as new resistance mechanisms are described.  
Whatever the molecular method used, it is critically important to ensure that the PCR either 
detects all currently known mcr genes or that the databases used to impute resistance 
mechanisms from whole-genome sequencing data are up to date.  
As our understanding of colistin resistance mechanisms improves, so will the concordance 
between phenotypic and genotypic test results. As for many other classes of antimicrobial 
agent, molecular testing may eventually offer an alternative to phenotypic testing for the 
surveillance of colistin resistance. Nevertheless, if the results are intended to guide clinical 
management, inference of phenotype based solely on a genotypic result may be valid only 
when the genotypic result is positive (i.e. mechanisms or genes detected), with a cautionary 
note that the resistance phenotype is likely but not guaranteed. If the results of the genotypic 
test are negative, no inference should be drawn about phenotype.  
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4. Surveillance strategies  
In view of the many technical challenges to colistin susceptibility testing, clear strategies are 
required for clinical diagnosis, sampling and testing for surveillance. In local health care 
settings, colistin resistance should be tested if the recommended technology is available, 
and samples should be sent to laboratories with the necessary technical capacity if the 
technology is not available. The cost of shipping isolates is an important aspect to be 
considered in confirmatory testing. Testing should be performed on:  
• carbapenem-resistant Enterobacteriaceae (except for intrinsically colistin-resistant 
genera),  
• other Gram-negative bacteria resistant to carbapenems (except intrinsically colistin-
resistant genera) and,  
• when treatment with colistin must be considered (except infections caused by 
intrinsically colistin-resistant genera).  
Health care facilities with a high prevalence or outbreaks of infections caused by 
carbapenem-resistant and other multidrug-resistant Enterobacteriaceae and/or non-
fermenting bacteria such as Acinetobacter baumannii spp. and P. aeruginosa, could 
consider conducting periodic surveys to assess the occurrence of colistin resistance to 
inform local antimicrobial use policies. 
At national level, at least one AMR reference laboratory should be established to monitor 
colistin resistance reliably, with appropriate controls and standardized methods. Such an 
AMR reference laboratory could perform confirmatory testing upon request from local 
laboratories. Samples for confirmatory testing should be selected carefully, with priority given 
to isolates suspected to have acquired transferrable (mcr-mediated) colistin resistance. A 
reasonable strategy for detecting mcr-mediated colistin resistance would be to screen for 
phenotypic resistance (for example, using selective agar plates), CHROMID® Colistin R 
agar, Superpolymyxin or CHROMagar COL-APSE) (60, 61, 68, 69), followed by PCR to 
detect one or more of the mcr genes. Such molecular testing could be performed at a 
reference laboratory or at a WHO collaborating centre. 
Ideally, colistin susceptibility testing should be included in national plans for AMR 
surveillance. Countries with strong national AMR surveillance programmes and laboratory 
capacity could extend them to include monitoring for colistin resistance in bacteria isolated 
from food-producing animals and also from food and environmental samples, at least 
periodically. 
Currently, the detection of colistin resistance is too technically complicated to recommend as 
a phenotypic screening method for resource-limited settings. It is therefore essential that 
laboratories store isolates suspected of being colistin-resistant and collaborate with AMR 
reference laboratories and/or WHO collaborating centres to confirm colistin resistance and 
determine the possible presence of mcr genes.  
The GLASS protocol (64) for sample-based surveillance is recommended for colistin 
susceptibility testing. In sample-based surveillance case-finding is focused on priority 
specimens sent routinely to laboratories for clinical purposes. In addition, epidemiological 
information should be clearly linked to microbiological information for each sample and the 
standard AMR indicators recorded for positive cultures. The sample-based approach allows 
acquisition of information on the proportion of susceptible, intermediate and resistant isolates 
and the total number of patients sampled, making it possible to deduce the rates or 
frequencies of specific types of resistance in the tested population. Information on the 
incidence of this type of resistance among tested patients could provide an indication of the 
extent of colistin resistance in the population. The sample population must be carefully 
defined and described in any report in order not to overestimate resistance rates if only 
highly resistant strains are tested. 
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